Arcturus Therapeutics - ARCT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $28.25
  • Forecasted Upside: 33.00%
  • Number of Analysts: 8
  • Breakdown:
  • 3 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$21.24
▼ -0.73 (-3.32%)

This chart shows the closing price for ARCT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arcturus Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARCT

Analyst Price Target is $28.25
▲ +33.00% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Arcturus Therapeutics in the last 3 months. The average price target is $28.25, with a high forecast of $44.00 and a low forecast of $14.00. The average price target represents a 33.00% upside from the last price of $21.24.

This chart shows the closing price for ARCT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 8 contributing investment analysts is to hold stock in Arcturus Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 5 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 5 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 5 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 3 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 3 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 3 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 3 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 3 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/14/2022Wells Fargo & CompanyInitiated CoverageOverweight$35.00Low
11/10/2022The Goldman Sachs GroupBoost TargetSell$8.00 ➝ $14.00Low
11/10/2022Robert W. BairdDowngradeNeutral ➝ Underperform$18.00Low
11/3/2022CitigroupUpgradeNeutral ➝ Buy$22.00 ➝ $35.00Low
11/2/2022BarclaysUpgradeUnderweight ➝ Equal Weight$16.00 ➝ $25.00Low
11/2/2022Cantor FitzgeraldBoost TargetOverweight$39.00 ➝ $44.00Low
8/10/2022Brookline Capital ManagementReiterated RatingBuyLow
8/10/2022Wells Fargo & CompanyLower TargetOverweight$105.00 ➝ $98.00Low
8/10/2022BarclaysLower TargetUnderweight$17.00 ➝ $16.00Low
8/10/2022Raymond JamesDowngradeMarket Perform ➝ UnderperformLow
5/24/2022The Goldman Sachs GroupLower TargetSell$14.00 ➝ $8.00High
5/11/2022GuggenheimLower Target$83.00 ➝ $36.00High
5/11/2022Robert W. BairdUpgradeUnderperform ➝ Neutral$21.00 ➝ $18.00High
5/10/2022BarclaysLower Target$21.00 ➝ $17.00High
5/10/2022HC WainwrightLower Target$25.00 ➝ $19.00High
5/9/2022Cantor FitzgeraldReiterated RatingOverweightHigh
4/21/2022CitigroupDowngradeBuy ➝ Neutral$86.00 ➝ $29.00High
3/25/2022Wells Fargo & CompanyLower TargetOverweight$107.00 ➝ $105.00Medium
3/15/2022CitigroupLower TargetBuy$114.00 ➝ $86.00Low
3/1/2022HC WainwrightLower Target$47.00 ➝ $25.00High
3/1/2022Wells Fargo & CompanyLower TargetOverweight$118.00 ➝ $107.00Low
3/1/2022Cantor FitzgeraldLower Target$93.00 ➝ $86.00Low
3/1/2022BarclaysLower Target$31.00 ➝ $21.00Low
1/31/2022Raymond JamesUpgradeUnderperform ➝ Market PerformHigh
1/26/2022HC WainwrightLower Target$47.00 ➝ $33.00High
11/16/2021Cantor FitzgeraldBoost TargetOverweight$85.00 ➝ $93.00Low
11/9/2021BarclaysLower TargetPositive ➝ Underweight$46.00 ➝ $31.00High
8/25/2021CitigroupLower TargetBuy$118.00 ➝ $114.00High
8/12/2021Raymond JamesDowngradeMarket Perform ➝ UnderperformHigh
8/10/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$29.00High
8/10/2021Cantor FitzgeraldBoost TargetOverweight$71.00 ➝ $85.00High
8/10/2021Robert W. BairdDowngradeNeutral ➝ Underperform$31.00High
7/2/2021Cantor FitzgeraldInitiated CoverageOverweight$71.00High
6/24/2021The Goldman Sachs GroupInitiated CoverageNeutral$29.00 ➝ $34.00Low
6/21/2021BarclaysDowngradeEqual Weight ➝ Underweight$33.00 ➝ $25.00High
5/12/2021B. RileyReiterated RatingSell$35.00 ➝ $23.00Low
5/11/2021BarclaysLower TargetEqual Weight$46.00 ➝ $33.00High
3/8/2021B. RileyLower TargetPositive ➝ Sell$45.00 ➝ $35.00Low
3/2/2021Roth CapitalLower TargetSell$77.00 ➝ $45.00Low
2/17/2021B. RileyDowngradeNeutral ➝ SellLow
1/15/2021B. RileyDowngradeBuy ➝ Neutral$138.00 ➝ $77.00Medium
1/7/2021Wells Fargo & CompanyInitiated CoverageOverweight$118.00N/A
12/29/2020HC WainwrightDowngradeBuy ➝ Neutral$84.00 ➝ $50.00N/A
12/29/2020Robert W. BairdDowngradeOutperform ➝ Neutral$79.00 ➝ $69.00N/A
12/29/2020BarclaysDowngradeOverweight ➝ Equal Weight$68.00 ➝ $46.00N/A
12/29/2020Raymond JamesDowngradeOutperform ➝ Market Perform$46.00N/A
12/23/2020Roth CapitalDowngradeBuy ➝ Sell$77.00N/A
12/14/2020Smith Barney CitigroupBoost Target$62.00 ➝ $133.00Medium
12/7/2020B. RileyBoost TargetBuy$64.00 ➝ $111.00High
11/11/2020B. RileyLower TargetBuy$82.00 ➝ $64.00High
11/10/2020Raymond JamesLower TargetOutperform$79.00 ➝ $73.00High
10/26/2020BarclaysInitiated CoverageOverweight$72.00Medium
10/6/2020CitigroupInitiated CoverageBuy ➝ Buy$65.00High
8/25/2020Piper SandlerInitiated CoverageOverweight$77.00Medium
8/12/2020B. RileyBoost Target$70.00 ➝ $82.00Medium
8/11/2020Brookline Capital ManagementReiterated RatingBuyLow
8/11/2020Raymond JamesBoost TargetOutperform$72.00 ➝ $79.00High
8/11/2020HC WainwrightReiterated RatingBuy$78.00High
7/30/2020Roth CapitalInitiated CoverageBuy$77.00Medium
7/24/2020Raymond JamesReiterated RatingBuyHigh
7/24/2020HC WainwrightBoost TargetBuy$62.00 ➝ $78.00High
7/16/2020Raymond JamesInitiated CoverageOutperform$72.00Medium
7/12/2020B. RileyInitiated CoverageBuy$70.00High
6/9/2020WBB SecuritiesDowngradeBuy ➝ Hold$31.00Low
5/4/2020HC WainwrightReiterated RatingBuy$62.00Low
4/28/2020HC WainwrightBoost TargetBuy$26.00 ➝ $62.00High
4/14/2020HC WainwrightBoost TargetBuy$24.00 ➝ $26.00High
3/18/2020Robert W. BairdReiterated RatingBuy$26.00High
3/12/2020HC WainwrightBoost TargetBuy$18.00 ➝ $24.00High
3/5/2020LADENBURG THALM/SH SHBoost Target$22.00 ➝ $28.00High
3/4/2020HC WainwrightReiterated RatingBuy$18.00High
3/4/2020Roth CapitalBoost TargetBuy$14.00 ➝ $24.00High
2/10/2020Robert W. BairdInitiated CoverageOutperform$24.00High
2/6/2020GuggenheimInitiated CoverageBuy$19.00High
1/9/2020HC WainwrightReiterated RatingBuy$18.00Low
8/16/2019HC WainwrightSet TargetBuy$18.00High
8/7/2019HC WainwrightBoost TargetBuy$16.00 ➝ $18.00Medium
7/24/2019Brookline Capital ManagementReiterated RatingBuyHigh
6/20/2019Chardan CapitalSet TargetBuy$18.00High
4/5/2019HC WainwrightInitiated CoverageBuy ➝ Buy$15.00Low
3/19/2019Chardan CapitalReiterated RatingBuy$18.00Medium
2/20/2019Roth CapitalReiterated RatingBuyMedium
2/19/2019LaidlawInitiated CoverageBuyLow
9/27/2018Brookline Capital ManagementReiterated RatingBuyLow
9/20/2018WBB SecuritiesUpgradeBuy ➝ Strong-BuyLow
6/11/2018WBB SecuritiesUpgradeHold ➝ BuyMedium
5/31/2018LADENBURG THALM/SH SHUpgradeNeutral ➝ BuyHigh
2/28/2018LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralLow
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.93 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/11/2022
  • 6 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/10/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/10/2022
  • 6 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/9/2022
  • 3 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
12/9/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/8/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Arcturus Therapeutics logo
Arcturus Therapeutics Holdings, Inc. develops pharmaceuticals. It is a clinical-stage mRNA medicines and vaccines company, which focuses on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The firm's products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $21.24
Low: $21.21
High: $22.80

50 Day Range

MA: $18.50
Low: $16.24
High: $22.91

52 Week Range

Now: $21.24
Low: $11.70
High: $31.41

Volume

426,347 shs

Average Volume

358,481 shs

Market Capitalization

$564.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Arcturus Therapeutics?

The following Wall Street research analysts have issued research reports on Arcturus Therapeutics in the last twelve months: Barclays PLC, Brookline Capital Management, Cantor Fitzgerald, Citigroup Inc., Guggenheim, HC Wainwright, Raymond James, Robert W. Baird, StockNews.com, The Goldman Sachs Group, Inc., and Wells Fargo & Company.
View the latest analyst ratings for ARCT.

What is the current price target for Arcturus Therapeutics?

8 Wall Street analysts have set twelve-month price targets for Arcturus Therapeutics in the last year. Their average twelve-month price target is $28.25, suggesting a possible upside of 33.0%. Cantor Fitzgerald has the highest price target set, predicting ARCT will reach $44.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $14.00 for Arcturus Therapeutics in the next year.
View the latest price targets for ARCT.

What is the current consensus analyst rating for Arcturus Therapeutics?

Arcturus Therapeutics currently has 3 sell ratings, 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ARCT, but not buy more shares or sell existing shares.
View the latest ratings for ARCT.

What other companies compete with Arcturus Therapeutics?

How do I contact Arcturus Therapeutics' investor relations team?

Arcturus Therapeutics' physical mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 900-2660 and its investor relations email address is [email protected] The official website for Arcturus Therapeutics is www.arcturusrx.com. Learn More about contacing Arcturus Therapeutics investor relations.